• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α2-肾上腺素能受体在肝纤维化中的作用:对肾上腺素能阻滞剂美司亭的影响。

α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin.

机构信息

Department of Clinical Pharmacology, University Hospital of Tuebingen, 72076 Tuebingen, Germany.

Department of Medical Chemistry, Yerevan State Medical University, 0025 Yerevan, Armenia.

出版信息

Cells. 2020 Feb 18;9(2):456. doi: 10.3390/cells9020456.

DOI:10.3390/cells9020456
PMID:32085378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7072854/
Abstract

The noradrenergic system is proposed to play a prominent role in the pathogenesis of liver fibrosis. While α1- and β-adrenergic receptors (ARs) are suggested to be involved in a multitude of profibrogenic actions, little is known about α2-AR-mediated effects and their expression pattern during liver fibrosis and cirrhosis. We explored the expression of α2-AR in two models of experimental liver fibrosis. We further evaluated the capacity of the α2-AR blocker mesedin to deactivate hepatic stellate cells (HSCs) and to increase the permeability of human liver sinusoidal endothelial cells (hLSECs). The mRNA of α2a-, α2b-, and α2c-AR subtypes was uniformly upregulated in carbon tetrachloride-treated mice vs the controls, while in bile duct-ligated mice, only α2b-AR increased in response to liver injury. In murine HSCs, mesedin led to a decrease in α-smooth muscle actin, transforming growth factor-β and α2a-AR expression, which was indicated by RT-qPCR, immunocytochemistry, and Western blot analyses. In a hLSEC line, an increased expression of endothelial nitric oxide synthase was detected along with downregulated transforming growth factor-β. In conclusion, we suggest that the α2-AR blockade alleviates the activation of HSCs and may increase the permeability of liver sinusoids during liver injury.

摘要

去甲肾上腺素能系统被认为在肝纤维化的发病机制中起重要作用。虽然 α1-和 β-肾上腺素受体(AR)被认为参与了多种促纤维化作用,但对于 α2-AR 介导的作用及其在肝纤维化和肝硬化中的表达模式知之甚少。我们在两种实验性肝纤维化模型中研究了 α2-AR 的表达。我们进一步评估了 α2-AR 阻滞剂美司汀激活肝星状细胞(HSCs)和增加人肝窦内皮细胞(hLSECs)通透性的能力。与对照组相比,四氯化碳处理的小鼠中 α2a-、α2b-和 α2c-AR 亚型的 mRNA 均均匀上调,而在胆管结扎的小鼠中,只有 α2b-AR 对肝损伤有反应而增加。在小鼠 HSCs 中,美司汀导致 α-平滑肌肌动蛋白、转化生长因子-β和 α2a-AR 的表达减少,这通过 RT-qPCR、免疫细胞化学和 Western blot 分析得到证实。在 hLSEC 系中,检测到内皮型一氧化氮合酶的表达增加,同时转化生长因子-β的表达下调。总之,我们认为 α2-AR 阻断减轻了 HSCs 的激活,并可能在肝损伤期间增加肝窦的通透性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/727578e76ecf/cells-09-00456-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/4635a6fb083b/cells-09-00456-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/8092444daeda/cells-09-00456-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/ab6360c8b8c0/cells-09-00456-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/75184c09eabc/cells-09-00456-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/dd37291c8e85/cells-09-00456-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/727578e76ecf/cells-09-00456-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/4635a6fb083b/cells-09-00456-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/8092444daeda/cells-09-00456-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/ab6360c8b8c0/cells-09-00456-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/75184c09eabc/cells-09-00456-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/dd37291c8e85/cells-09-00456-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7572/7072854/727578e76ecf/cells-09-00456-g006.jpg

相似文献

1
α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin.α2-肾上腺素能受体在肝纤维化中的作用:对肾上腺素能阻滞剂美司亭的影响。
Cells. 2020 Feb 18;9(2):456. doi: 10.3390/cells9020456.
2
Neuroprotective, Neurogenic, and Amyloid Beta Reducing Effect of a Novel Alpha 2-Adrenoblocker, Mesedin, on Astroglia and Neuronal Progenitors upon Hypoxia and Glutamate Exposure.新型 α2 肾上腺素能阻滞剂美司丁对缺氧和谷氨酸暴露时的星形胶质细胞和神经祖细胞的神经保护、神经发生和淀粉样β 降低作用。
Int J Mol Sci. 2017 Dec 21;19(1):9. doi: 10.3390/ijms19010009.
3
Inhibition of α2A-Adrenoceptors Ameliorates Dextran Sulfate Sodium-Induced Acute Intestinal Inflammation in Mice.抑制α2A肾上腺素能受体可改善葡聚糖硫酸钠诱导的小鼠急性肠道炎症。
J Pharmacol Exp Ther. 2016 Sep;358(3):483-91. doi: 10.1124/jpet.116.235101. Epub 2016 Jul 14.
4
Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice.α2A肾上腺素能受体基因敲除小鼠交感神经系统的异常调节
Mol Pharmacol. 1999 Jul;56(1):154-61. doi: 10.1124/mol.56.1.154.
5
Different roles of alpha2-adrenoceptor subtypes in non-pregnant and late-pregnant uterine contractility in vitro in the rat.α2-肾上腺素能受体亚型在大鼠非妊娠和妊娠晚期子宫体外收缩中的不同作用
Neurochem Int. 2007 Oct;51(5):311-8. doi: 10.1016/j.neuint.2007.06.029. Epub 2007 Jul 1.
6
α-adrenergic blockade attenuates septic cardiomyopathy by increasing cardiac norepinephrine concentration and inhibiting cardiac endothelial activation.α-肾上腺素能阻断通过增加心脏去甲肾上腺素浓度和抑制心脏内皮细胞激活来减轻脓毒症性心肌病。
Sci Rep. 2018 Apr 3;8(1):5478. doi: 10.1038/s41598-018-23304-7.
7
A study of presynaptic alpha2-autoreceptors in alpha2A/D-, alpha2B- and alpha2C-adrenoceptor-deficient mice.α2A/D -、α2B -和α2C -肾上腺素能受体缺陷小鼠中突触前α2 -自身受体的研究
Naunyn Schmiedebergs Arch Pharmacol. 2001 Aug;364(2):117-30. doi: 10.1007/s002100100423.
8
The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.慢性肾上腺素治疗后,β2肾上腺素能受体的存在会使α2A肾上腺素能受体对脱敏敏感。
BMC Pharmacol. 2007 Dec 20;7:16. doi: 10.1186/1471-2210-7-16.
9
α2C-adrenoceptor modulators: a patent review.α2C-肾上腺素受体调节剂:专利研究综述。
Expert Opin Ther Pat. 2011 Apr;21(4):455-81. doi: 10.1517/13543776.2011.565333.
10
Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells.功能性α2 - 肾上腺素能受体亚型在人阴茎海绵体及培养的小梁平滑肌细胞中的表达。
Recept Signal Transduct. 1997;7(1):55-67.

引用本文的文献

1
Pharmacological Modulation of Liver and Spleen Stiffness in a Cirrhotic Rat Model.肝硬化大鼠模型中肝脏和脾脏硬度的药理学调节
Hepat Med. 2025 Sep 11;17:91-104. doi: 10.2147/HMER.S541039. eCollection 2025.
2
Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor.NEU3 抑制剂抑制 CCl4 诱导的肝炎症和纤维化。
PLoS One. 2024 Nov 21;19(11):e0308060. doi: 10.1371/journal.pone.0308060. eCollection 2024.
3
Manifestations of Liver Impairment and the Effects of MH-76, a Non-Quinazoline α1-Adrenoceptor Antagonist, and Prazosin on Liver Tissue in Fructose-Induced Metabolic Syndrome.

本文引用的文献

1
Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis.白细胞介素-10 通过 STAT3-p53 通路诱导活化的肝星状细胞衰老,从而减轻肝纤维化。
Cell Signal. 2020 Feb;66:109445. doi: 10.1016/j.cellsig.2019.109445. Epub 2019 Nov 12.
2
Dexmedetomidine protects against lipopolysaccharide-induced early acute kidney injury by inhibiting the iNOS/NO signaling pathway in rats.右美托咪定通过抑制大鼠诱导型一氧化氮合酶/一氧化氮信号通路来防止脂多糖诱导的早期急性肾损伤。
Nitric Oxide. 2019 Apr 1;85:1-9. doi: 10.1016/j.niox.2019.01.009. Epub 2019 Jan 17.
3
Dexmedetomidine attenuates lipopolysaccharide-induced liver oxidative stress and cell apoptosis in rats by increasing GSK-3β/MKP-1/Nrf2 pathway activity via the α2 adrenergic receptor.
肝损伤的表现以及非喹唑啉α1-肾上腺素能受体拮抗剂MH-76和哌唑嗪对果糖诱导的代谢综合征大鼠肝组织的影响
Metabolites. 2023 Nov 3;13(11):1130. doi: 10.3390/metabo13111130.
4
GPCRs and fibroblast heterogeneity in fibroblast-associated diseases.GPCRs 与成纤维细胞相关疾病中的成纤维细胞异质性。
FASEB J. 2023 Aug;37(8):e23101. doi: 10.1096/fj.202301091.
5
Dexmedetomidine Promotes Lipopolysaccharide-Induced Differentiation of Cardiac Fibroblasts and Collagen I/III Synthesis through α Adrenoreceptor-Mediated Activation of the PKC-p38-Smad2/3 Signaling Pathway in Mice.右美托咪定通过激活 PKCP38-Smad2/3 信号通路促进脂多糖诱导的心肌成纤维细胞分化和胶原 I/III 的合成。
Int J Mol Sci. 2021 Nov 25;22(23):12749. doi: 10.3390/ijms222312749.
6
Dexmedetomidine attenuates sepsis-associated inflammation and encephalopathy via central α2A adrenoceptor.右美托咪定通过中枢 α2A 肾上腺素能受体减轻脓毒症相关性炎症和脑病。
Brain Behav Immun. 2021 Jan;91:296-314. doi: 10.1016/j.bbi.2020.10.008. Epub 2020 Oct 8.
7
Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis".专题:“肝纤维化发病机制的细胞和分子机制”
Cells. 2020 Apr 29;9(5):1105. doi: 10.3390/cells9051105.
右美托咪定通过α2 肾上腺素能受体增加 GSK-3β/MKP-1/Nrf2 通路活性,从而减轻脂多糖诱导的大鼠肝氧化应激和细胞凋亡。
Toxicol Appl Pharmacol. 2019 Feb 1;364:144-152. doi: 10.1016/j.taap.2018.12.017. Epub 2018 Dec 28.
4
Neuroprotective, Neurogenic, and Amyloid Beta Reducing Effect of a Novel Alpha 2-Adrenoblocker, Mesedin, on Astroglia and Neuronal Progenitors upon Hypoxia and Glutamate Exposure.新型 α2 肾上腺素能阻滞剂美司丁对缺氧和谷氨酸暴露时的星形胶质细胞和神经祖细胞的神经保护、神经发生和淀粉样β 降低作用。
Int J Mol Sci. 2017 Dec 21;19(1):9. doi: 10.3390/ijms19010009.
5
Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway.咪唑啉I2受体抑制剂伊达唑胺通过Akt-Nrf2-Smad2/3信号通路调节肝纤维化的进程。
Oncotarget. 2017 Mar 28;8(13):21015-21030. doi: 10.18632/oncotarget.15472.
6
Hepatocyte Hypoxia Inducible Factor-1 Mediates the Development of Liver Fibrosis in a Mouse Model of Nonalcoholic Fatty Liver Disease.肝细胞缺氧诱导因子-1介导非酒精性脂肪性肝病小鼠模型中肝纤维化的发展。
PLoS One. 2016 Dec 28;11(12):e0168572. doi: 10.1371/journal.pone.0168572. eCollection 2016.
7
Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis.白皮杉醇可增加肝细胞生长因子和白细胞介素-10的表达,从而在硫代乙酰胺诱导的肝纤维化中保护肝细胞。
Can J Physiol Pharmacol. 2016 Jul;94(7):779-87. doi: 10.1139/cjpp-2016-0001. Epub 2016 Mar 5.
8
TGF-β signalling and liver disease.转化生长因子-β信号传导与肝脏疾病
FEBS J. 2016 Jun;283(12):2219-32. doi: 10.1111/febs.13665. Epub 2016 Feb 22.
9
Sympathetic Nervous System Control of Carbon Tetrachloride-Induced Oxidative Stress in Liver through α-Adrenergic Signaling.交感神经系统通过α-肾上腺素能信号传导对四氯化碳诱导的肝脏氧化应激的控制
Oxid Med Cell Longev. 2016;2016:3190617. doi: 10.1155/2016/3190617. Epub 2015 Dec 21.
10
Beta blockers in cirrhosis: The window re-opens.肝硬化中的β受体阻滞剂:机会再次出现。
J Hepatol. 2016 Mar;64(3):532-4. doi: 10.1016/j.jhep.2015.12.012. Epub 2015 Dec 24.